Overview

COVID-19 Long-Haulers Study

Status:
Completed

Trial end date:
2021-07-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.

Phase:

Phase 2

Details

Lead Sponsor:

CytoDyn, Inc.

Collaborator:

Amarex Clinical Research

Treatments:

Leronlimab